GlassScriptPhysician profile
Heather Allen
NPI 1366196602
$3,292.31
in general payments reported to CMS, 2019-2025
22 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $297 · 2023: $501 · 2024: $1,277 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,995.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $640.87 | 2023-2025 | Belbuca, Xtampza |
| Abbvie INC. | $564.05 | 2023-2025 | |
| Ibsa Pharma INC. | $258.73 | 2024-2025 | Tirosint, Licart, Flector |
| Pfizer INC. | $256.47 | 2024-2025 | |
| Medtronic, INC. | $242.21 | 2022-2024 | Intellis Adaptivestim, Synchromedii |
| Novo Nordisk INC | $225.64 | 2023-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.64 | 2023-2025 | Relistor |
| Boston Scientific Corporation | $138.45 | 2022-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Axsome Therapeutics, INC. | $95.00 | 2025 | Symbravo |
| Valinor Pharma, LLC | $91.88 | 2024 | Movantik |
| Merz Pharmaceuticals, LLC | $78.53 | 2023-2025 | Xeomin |
| Virtus Pharmaceuticals LLC | $73.49 | 2023 | Levorphanol Tartrate |
| Forte Bio-Pharma LLC | $72.43 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Scilex Pharmaceuticals INC. | $68.78 | 2024-2025 | |
| Si-Bone, INC. | $47.48 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $44.98 | 2025 | |
| Azurity Pharmaceuticals, INC. | $41.25 | 2023-2024 | Horizant, Horizant |
| Saluda Medical Americas, INC. | $37.38 | 2024-2025 | Evoke |
| Protega Pharmaceutials INC | $28.85 | 2023 | Roxybond |
| Avanos Medical | $24.71 | 2024 | Standard Rf Disposables |
| Stryker Corporation | $22.90 | 2024 | Mild Device Kit |
| Amneal Pharmaceuticals LLC | $16.59 | 2023 | Lyvispah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.